Please use this identifier to cite or link to this item:
|Title:||Novel VEGF signalling inhibitors: how helpful are biomarkers in their early development?|
|Citation:||EXPERT OPIN INVESTIG DRUGS, 2009, 18 (11), pp. 1701-1714|
|Abstract:||The development of vascular endothelial growth factor (VEGF) inhibitors of tumour angiogenesis can only be described as prolific. It is therefore interesting to speculate which will reach the clinic. Of course, the most effective agents will succeed, but how is effectiveness measured? When presented with a summary of competitive compounds, it can be difficult to discriminate between their potency on target, toxicity and response rates.|
|Appears in Collections:||Published Articles, Dept. of Cancer Studies and Molecular Medicine|
Files in This Item:
There are no files associated with this item.
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.